Breakthrough in Cancer Gene Therapy: Mesenchymal Stem Cells Show Promise in Targeting Solid Tumors

Researchers at Kobe Pharmaceutical University have made a significant discovery in the field of cancer gene therapy, using mesenchymal stem cells (MSCs) to target solid tumors. In a new report, the team revealed that MSCs can be used as biomimetic carriers for active drug delivery systems, loading liposomes onto their surface to deliver anti-cancer drugs. This novel approach has shown promising results in treating melanoma in mouse tumor models.

Key Takeaways:

• The study demonstrated that MSCs can accumulate in solid melanoma tumors with low vascular permeability, making them an efficient carrier for anti-cancer drugs.
• The researchers loaded liposomes onto the surface of MSCs, creating liposome-loaded MSCs (Lip-MSCs) that can carry a larger amount of doxorubicin (DOX) with minimal cytotoxicity.
• DOX-loaded Lip-MSCs showed sustained DOX release and efficiently migrated toward the conditioned medium of B16/BL6 melanoma cells in vitro and accumulated in B16/BL6 tumors in vivo, leading to a significant inhibitory effect on tumor growth.
• The study concluded that Lip-MSCs can serve as an efficient carrier to deliver anti-cancer drugs into solid tumors.
• The researchers utilized 100 nm DOX-Lip for the preparation of DOX-Lip-MSCs, which showed higher DOX-loading capacity and sustained DOX release compared to MSCs loaded with DOX by incubation with DOX solution.

Statistics:

• 100 nm DOX-Lip showed higher DOX-loading capacity (27.1 ± 3.4 μg/mg) compared to MSCs loaded with DOX by incubation with DOX solution (6.5 ± 1.2 μg/mg).
• DOX-Leakage from 600 nm-sized liposomes was significant, while smaller liposomes (100 nm) retained DOX.
• DOX-Lip-MSCs accumulated in B16/BL6 tumors in vivo, leading to a significant inhibitory effect on tumor growth.
• The study used a mouse tumor model of melanoma, with B16/BL6 cells being the melanoma cell line used.

Sources:

• Liposome-Loaded Mesenchymal Stem Cells Enhance Tumor Accumulation and Anti-Tumor Efficacy of Doxorubicin in Mouse Tumor Models of Melanoma. Pharmaceutics, 2025,17(8):947.
• MDPI AG, the publisher for Pharmaceutics.
• Kobe Pharmaceutical University, Kobe, Japan.